Bolt Therapeutics Conference Call - BOLT BIOTHERAPEUTICS INC

Explicit Guidance:

• Capital & Runway: The $120 million upfront private placement proceeds are expected to fund operations through 2025 (referenced as "2020E" in transcript, likely a transcription error for 2025 given the context of 2027 milestones).
• Additional Financing: Potential for up to $60 million in gross proceeds upon exercise of warrants accompanying the current private placement.
• Clinical Milestones: Patient proof-of-concept (PoC) data for PRA216 across asthma, COPD, atopic dermatitis, and eosinophilic esophagitis (EOE) studies is expected beginning in the second quarter of 2027, with data releases continuing through the fourth quarter of 2027.
• Secondary Program: Movement of the IL-31 bispecific program into the clinic and generation of initial clinical data expected in the second half of 2027.
• Pipeline Advancement: Programs 3 and 4 (new candidates from INSPIRE platform) expected to advance through IND-enabling development in the second half of 2027.
• Phase III Timeline: Pivotal Phase III trials for PRA216 anticipated to initiate in early 2028.
• Capex/Opex: No specific FY2027 revenue, earnings, margin, or tax rate guidance provided; capital allocation is defined by the transaction financing and operational runway.

Business-Segment Outlook:

• Primary Focus: Prana Therapies' pipeline, specifically next-generation, half-life-extended multispecific antibodies, will become the company's primary development focus following the reverse merger.
• Lead Asset (PRA216): Phase II development ongoing for asthma, COPD, and atopic dermatitis; EOE study planned.
• Dosing Strategy: Phase II trials evaluating an every 8-week maintenance dosing regimen; future trials may evaluate every 12-week intervals.
• Product Architecture: INSPIRE platform focuses on fully human IgG-based architecture to enable high concentration, subcutaneous formulation, and durable efficacy for chronic diseases.
• Market Segments: Targeting large global markets with hundreds of millions of patients (asthma, COPD, atopic dermatitis) where unmet need exists despite existing biologics.

Market and Competitive Outlook:

• Differentiation Strategy: Aiming to move beyond the efficacy ceiling of monotherapies by combining IL-4 receptor alpha and TSLP blockade to address heterogeneous patient populations and comorbid atopic conditions.
• Competitive Positioning: Differentiation sought through "durable exposure" and "convenient at-home dosing" (auto-injector) compared to existing bispecific formats; claims of improved stability and manufacturability via the INSPIRE scaffold.
• Value Proposition: Potential to treat primary disease and comorbidities simultaneously, addressing a gap in current standard-of-care biologics.

Macro / Industry Outlook:

• Management Tone: Expects a "catalyst-rich 2027 and beyond," signaling confidence in the near-term clinical timeline and platform validation.
• Industry Trends: Acknowledges the value of targeting type 2 inflammation but highlights that existing monotherapies leave "meaningful room for improvement" in reducing exacerbation rates and patient outcomes.

Strategic Initiatives:

• M&A/Transaction: Completed a stock-for-stock reverse merger acquiring Prana Therapies; non-voting convertible preferred stock (subject to stockholder approval) is expected to convert to BOLT common stock.
• Leadership Changes: Dr. Sheila Gujarati (former Prana CEO) appointed as Chief Strategy Officer and joined the Bolt board; full Prana team integrated.
• Platform Expansion: INSPIRE platform expected to generate new wholly-owned programs, with Programs 3 and 4 advancing to IND-enabling stages.
• Phase III Preparation: Phase III enabling activities already in progress to ensure efficient transition from Phase II to pivotal trials.

Risks and Headwinds to Outlook:

• Clinical Execution: Future data readouts (2027) are subject to the success of Phase II trials in proving efficacy and safety in patient populations.
• Regulatory/Approval: Success is contingent upon obtaining stockholder approval for the conversion of preferred stock to common stock.
• Development Uncertainty: The "potential" for improved dosing intervals (12 weeks) and broader disease coverage are based on modeling and preclinical data, not yet confirmed in patients.
• General Forward-Looking Statement Risks: All remarks are subject to risks and uncertainties described in Bolt's SEC filings and press releases, including those related to the transaction, financing, and anticipated clinical milestones.

Management Tone on the Future:

• Confidence Level: High confidence in the platform's ability to deliver "best-in-disease" therapies and the team's ability to "efficiently execute."
• Pacing: Described the pace as "rapid," noting the transition from Phase I to Phase II occurred quickly following favorable safety and PK data.
• Strategic Narrative: Frames the 2027-2028 window as a period of "growth and value creation" driven by a "potentially best-in-disease lead program."

Miscellaneous:

• Dosing Modeling: Phase 2 dosing model (600mg Q8W) is intentionally conservative, assuming independent pathway inhibition without potential pharmacologic synergy.
• Safety Profile: Phase I data showed no serious adverse events or injection site reactions, supporting the "well-tolerated" narrative for patient studies.
• Target Product Profile: Aims for an every 8-to-12-week maintenance regimen with a single at-home auto-injector.